0000899243-20-032448.txt : 20201202 0000899243-20-032448.hdr.sgml : 20201202 20201202094508 ACCESSION NUMBER: 0000899243-20-032448 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201202 FILED AS OF DATE: 20201202 DATE AS OF CHANGE: 20201202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HUTCHISON PATRICK CENTRAL INDEX KEY: 0001673870 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34236 FILM NUMBER: 201362575 MAIL ADDRESS: STREET 1: C/O BIOSPECIFICS TECHNOLOGIES CORP STREET 2: 2 RIGHTER PARKWAY SUITE 200 CITY: WILMINGTON STATE: DE ZIP: 19803 FORMER NAME: FORMER CONFORMED NAME: Hutchison Patrick DATE OF NAME CHANGE: 20160504 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOSPECIFICS TECHNOLOGIES CORP CENTRAL INDEX KEY: 0000875622 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 113054851 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 35 WILBUR ST CITY: LYNBROOK STATE: NY ZIP: 11563 BUSINESS PHONE: 302-842-8450 MAIL ADDRESS: STREET 1: 2 RIGHTER PARKWAY, SUITE 200 CITY: WILMINGTON STATE: DE ZIP: 19803 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-12-02 1 0000875622 BIOSPECIFICS TECHNOLOGIES CORP BSTC 0001673870 HUTCHISON PATRICK C/O BIOSPECIFICS TECHNOLOGIES CORP. 2 RIGHTER PKWY, DE CORP CENTER II WILMINGTON DE 19803 0 1 0 0 Chief Financial Officer Stock Option (Right to Buy) 56.21 2020-12-02 4 D 0 10000 32.29 D 2030-01-06 Common Stock 10000 0 D Upon the consummation of the merger contemplated by that certain Agreement and Plan of Merger, by and among BioSpecifics Technologies Corp., Endo International plc, and Beta Acquisition Corp., dated October 19, 2020, the stock options, which provided for vesting in four equal annual installments following the grant date (January 6, 2020), were canceled in exchange for a cash payment of $322,900.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the stock options by (y) the amount by which the offer price ($88.50) exceeds the per share exercise price of such stock option. /s/ Patrick C. Hutchison, by Carl A. Valenstein, attorney-in-fact 2020-12-02